Close-up of glove hand holding a blue gel capsule while pipette drops liquid into a test tube.
Our Work

Latham & Watkins Advises BridgeBio on US$300 Million Strategic Royalty Sale of BEYONTTRA® European Royalties

July 1, 2025
Multidisciplinary team represents the biotech in one of the largest royalty transactions of 2025, with investors HealthCare Royalty and Blue Owl Capital.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a new type of biopharmaceutical company focused on genetic diseases, has announced it has sold a portion of royalties due to the Company from sales of BEYONTTRA in Europe to HealthCare Royalty (HCRx) and funds managed by Blue Owl Capital for US$300 million.

Latham & Watkins LLP represents BridgeBio in the transaction with a deal team led by partners Dan Van Fleet and Haim Zaltzman, with associates Tony Noh, William Lane, and Ian Drazen. Advice was also provided on intellectual property matters by counsel Robert Yeh, with associate Patrick Chew; on FDA regulatory matters by counsel Chad Jennings; on compliance matters by associate Leandra Joseph; on capital markets matters by partner Drew Capurro; and on tax matters by partner Eric Cho, with associate Sam Yang.

Endnotes

    Contacts

    Van Fleet, Dan

    Dan Van Fleet

    San Francisco / Silicon Valley
    dan.vanfleet@lw.com +1.415.391.0600
    Zaltzman, Haim

    Haim Zaltzman

    New York / San Francisco / Silicon Valley
    haim.zaltzman@lw.com